Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.63 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069599 | 0.93 | KCNH2 (0.76) | KCNH2LTB4RCYP19A1 | |
| SCHEMBL18924306 | 0.89 | KCNH2 (0.52) | KCNH2LTB4RCTSSCTSKNOS2 | |
| SCHEMBL1404092 | 0.86 | KCNH2 (0.83) | KCNH2NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL3625374 | 0.84 | GABRA1 (0.44) | KCNH2NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL10119370 | 0.84 | KCNH2 (0.52) | KCNH2LTB4RNOS2NOS1GABRA1 | |
| SCHEMBL14234024 | 0.82 | KCNH2 (0.76) | KCNH2NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL23140220 | 0.81 | KCNH2 (0.42) | KCNH2LTB4RNOS2NOS1GABRA1 | |
| SCHEMBL19182788 | 0.80 | CYP1A2 (0.47) | KCNH2NPSR1 | |
| SCHEMBL12641681 | 0.80 | KCNH2 (0.41) | KCNH2NOS2NOS1GABRA1GABRB2 | |
| SCHEMBL12445671 | 0.80 | KCNH2 (0.73) | KCNH2NOS2NOS1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299271-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10988531-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2021-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988531-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | KCNH2 4468/4885LTB4R 1101/4885CTSS 2123/4885 |
| US-20210299271-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | PCNA, EPCAM, MKI67 | KCNH2 4468/4885LTB4R 1101/4885CTSS 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.